Catalyst for a Cure Roundtable (CFC1)

These videos with the Catalyst for a Cure researchers were filmed during a roundtable interview discussion in January 2011 at the Palace Hotel in San Francisco.

Catalyst for a Cure (CFC1) Report: Nine Years of Innovation

The Catalyst For a Cure has reshaped the direction of glaucoma research by taking a pioneering approach that should become a model for research in other diseases.

Catalyst for a Cure 2011 Progress Report

The research team identified a period of vulnerability for retinal ganglion cells early in the disease, when these cells are more sensitive to metabolic insults and stressors.

Catalyst for a Cure Identifies Key Early Events in Glaucoma

During the year 2009, the investigators of the Catalyst for a Cure (CFC1) consortium worked together to probe how retinal ganglion cells are damaged and decline in glaucoma.

Brain Holds Early Signs of Glaucoma

In a recent study, David Calkins, PhD discovered that the first sign of injury in glaucoma actually occurs in the brain.

CFC Scientists Reply to Questions about Genetics and Glaucoma

The Catalyst For a Cure (CFC1) researchers are: David Calkins, PhD, Philip Horner, PhD, Nicholas Marsh-Armstrong, PhD, and Monica Vetter, PhD.

Study Proves Lowering IOP Preserves Vision

Before this study was done, there was a difference of opinion on whether intraocular pressure (IOP) was involved in optic nerve damage even when IOP was in the normal range.